Design and rationale of the LAPLACE-TIMI57 trial: A phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy

Clinical Cardiology

Volumn 35, Issue 7, 2012, Pages 385-391

  Kohli, Payal ^a   Desai, Nihar R ^a   Giugliano, Robert P ^a   Kim, Jae B ^b   Somaratne, Ransi ^b   Huang, Fannie ^b   Knusel, Beat ^b   McDonald, Shannon ^a   Abrahamsen, Timothy ^a   Wasserman, Scott M ^b   Scott, Robert ^b   Sabatine, Marc S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 145; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IMMUNOGLOBULIN G2A ANTIBODY; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 PROTEIN; PROTEINASE K; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; UNSPECIFIED SIDE EFFECT;

EID: 84863456755     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22014     Document Type: Article

References (32)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010; 121: 948-954.
2. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32: 1769-1818.
3. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Triallists' Collaborators. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010; 376: 1670-1681.
4. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Triallists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins [published corrections appear in Lancet. 2005; 366: 1358 and 2008;371:2084]. Lancet. 2005;366:1267- 1278.
5. Kearney PM, Blackwell L, Collins R, et al. Cholesterol Treatment Triallists' Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371: 117-125.
6. Ballantyne CM., Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol. 1998; 82: 3Q-12Q.
7. O'Keefe JH Jr, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normal. J Am Coll Cardiol. 2004; 43: 2142-2146. (Pubitemid 38686815)
8. Hsia J, MacFadyen JG, Monyak J, et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dL with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol. 2011; 57: 1666-1675.
9. Giraldez RR, Giugliano RP, Mohanavelu S, et al. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. J Am Coll Cardiol. 2008; 52: 914-920.
10. Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy [published correction appears in J Am Coll Cardiol. 2006; 47:472]. J Am Coll Cardiol. 2005;46: 1411-1416.
11. Wiviott SD, Mohanavelu S, Raichlen JS, et al. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study). Am J Cardiol. 2009; 104: 29-35.
12. Leeper NJ, Ardehali R, deGoma EM, et al. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. Circulation. 2007; 116: 613-618. (Pubitemid 47364579)
13. Bakker-Arkema RG, Nawrocki JW, Black DM., Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis. 2000; 149: 123-129. (Pubitemid 30125980)
14. Athyros VG, Tziomalos K, Karagiannis A, et al. Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association? Curr Opin Cardiol. 2010; 25: 406-410.
15. Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009; 120: 28-34.
16. 9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34: 154-156. (Pubitemid 36666925)
17. 9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006; 354: 1264-1272.
18. 9. Nat Genet. 2005; 37: 161-165.
19. 9 and identification of a compound heterozygote. Am J Hum Genet. 2006; 79: 514-523. (Pubitemid 44384260)
20. 9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007; 193: 445-448. (Pubitemid 47058112)
21. 9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol. 2010; 55: 2833-2842.
22. Denis M, Marcinkiewicz J, Zaid A, et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation. 2012; 125: 894-901.
23. Goldstein JL, Brown MS., The LDL receptor. Arterioscler Thromb Vasc Biol. 2009; 29: 431-438.
24. 9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004; 24: 1454-1459. (Pubitemid 39050440)
25. Awan Z, Seidah NG, MacFadyen JG, et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem. 2012; 58: 183-189.
26. Dias C SA, Smith B, Emery M, et al. A Phase 1, Randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability and pharmacodynamics of AMG145. Circulation (Suppl). 2011;124:A10701.
27. 9, on low-density lipoprotein cholesterol in subjects taking statins: A phase 1, randomized, double-blind, placebo-controlled, ascending Study. J Am Coll Cardiol (Suppl). 2012; 59: E1379.
28. 9 on LDL cholesterol. N Engl J Med. 2012; 366: 1108-1118.
29. McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;10.1016/j.jacc.2012.03.007.
30. Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J. 2011;162: 818. e6-825. e6.
31. 9: its role in LDL metabolism. Trends Biochem Sci. 2007; 32: 71-77. (Pubitemid 46199197)
32. 9) monoclonal antibody administered intravenously to healthy volunteers. Circulation (Suppl). 2010; 122: A23251.